tumor necrosis factor

Phase 3Small molecule

NNational Cancer Institute (NCI)

tumor necrosis factor is one of 150 small molecule programs targeting Necrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

NecrosisActive, not recruiting

MelanomaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

RhabdomyosarcomaActive, not recruiting

NecrosisPhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Soft Tissue SarcomaPhase 2

Active, not recruiting

RhabdomyosarcomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

11 2

Tuoyi

SSun Yat-sen University

Phase 3

4 3

KIMMTRAK

IImmunocore Ltd

Phase 3

2 4

HX008

BBinhui Biopharmaceutical Co., Ltd.

Phase 3

4 5

Investigator's Choice

Pfizer

Phase 3

1 6

tumor necrosis factor

NNational Cancer Institute (NCI)

Phase 3

1 7

Histamine Dihydrochloride

MMaxim Pharmaceuticals

Phase 3

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

Intron a

Merck & Co.

Preclinical

4 10

Opdualag

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00923351·44 enrolled

Melanoma1 trial

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001296·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for tumor necrosis factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tumor necrosis factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tumor necrosis factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

tumor necrosis factor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Necrosis2 trials

Soft Tissue Sarcoma1 trial

Rhabdomyosarcoma1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News